Universal reference book for medicines
Product name: DELAGIL

Active substance: chloroquine

Type: 4-aminoquinoline derivative.
Antimalarial and amebicidal drug.Immunodepressant
Manufacturer: ICN POLFA RZESZOW (Poland) manufactured by ALKALOIDA CHEMICAL COMPANY (Hungary)
Composition, form of production and packaging
Tablets
are flat, with a bevelled edge, white or almost white, odorless.

1 tab.

chloroquine (in the form of phosphate) 250 mg

Auxiliary substances: silicon dioxide colloidal hydrophobic (aerosil R972), polyacrylic acid (carbomer 934P), magnesium stearate, talc, polyvinylbutyral (movital B30T), corn starch.

10 pieces.
- blisters (3) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2005.

PHARMACHOLOGIC EFFECT

Anti-protozoal, it also has an immunosuppressive and anti-inflammatory effect.
Causes the death of asexual erythrocytic forms of all species of plasmodia. Has a gametocidal effect, with the exception of Plasmodium falciparum (exhibits antihametocidal effect).
PHARMACOKINETICS

After oral administration, it is quickly and almost completely absorbed from the digestive tract.
C max in the blood is reached after 2-6 hours. 55% is associated with albumin plasma. Rapidly spreads to the organs and tissues of the body (liver, kidneys, spleen, lungs). Easily penetrates through the BBB and the placenta. Metabolized in small amounts (25%). It is excreted by the kidneys (70% - unchanged) slowly. T 1/2 is 1-2 months. With kidney failure can cumulate.
INDICATIONS

- malaria (prevention and treatment of all types);

- Extraintestinal amebiasis;

- Amoebic liver abscess;

- systemic lupus erythematosus (chronic and subacute forms);

- rheumatoid arthritis;

scleroderma;

- photodermatosis.

DOSING MODE

Inside, for the prevention of malaria - for 0.5 g in the first week 2 times, then 1 time always on the same day of the week.

Treatment of malaria is carried out according to the following scheme: 1 day once 1 g, after 6-8 h - 0.5 g, on the 2nd and 3rd day of treatment - 0.75 g daily in one session.

With amebiasis , 0.5 g 3 times a day for 7 days, then 0.25 g 3 times a day for a further 7 days, then 0.75 g 2 times a week for 2-6 months.

With rheumatoid arthritis - 0.5 g 2 times / day for 7 days, then - 0.5 g daily for 12 months.

With systemic lupus erythematosus - daily, 0.25-0.5 g.

With photodermatosis , 0.25 g daily for a week, then 0.5-0.75 g weekly.

SIDE EFFECT

From the digestive system: nausea, vomiting, gastralgia.

From the nervous system: dizziness, headache, sleep disturbances, psychoses, epileptic seizures.

From the cardiovascular system: myocardial damage with changes on the ECG, lowering blood pressure.

From the senses : with prolonged use - corneal opacity, retinal damage, visual impairment, ringing in the ears.

Allergic reactions: dermatitis, photosensitivity.

Other: myalgia, leukopenia, discoloration of the skin and hair.

CONTRAINDICATIONS

hypersensitivity;

- liver failure;

- kidney failure;

- oppression of bone marrow hematopoiesis;

- severe rhythm disturbances;

- psoriatic arthritis;

- neutropenia;

- Porphyrinuria;

- Pregnancy;

- lactation.

With caution - a deficiency of glucose-6-phosphate dehydrogenase, retinopathy, epilepsy.

PREGNANCY AND LACTATION

The drug is contraindicated in pregnancy and lactation (breastfeeding).

APPLICATION FOR FUNCTIONS OF THE LIVER

Contraindicated in renal failure.

APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS

Contraindicated in liver failure.

SPECIAL INSTRUCTIONS

During treatment, systematic examinations of the ophthalmologist and general blood tests are necessary.

OVERDOSE

Symptoms: vomiting, impaired consciousness, visual disturbances, convulsions, collapse, oppression of the respiratory center, until the fatal outcome (within 2 hours of respiratory depression).

Treatment: invocation of vomiting, gastric lavage, intake of activated charcoal in a dose 5 times higher than the estimated dose of chloroquine;
peritoneal dialysis, plasmapheresis.
DRUG INTERACTION

Co-administration with phenylbutazone, gold preparations, penicillamine, cytostatics, levamisole increases the probability of bone marrow aplasia and skin lesions.

Antacids disrupt absorption, cimetidine increases the concentration of the drug in the blood.

Combination with other antimalarial drugs may be accompanied by antagonistic effect.

When combined with GCS, the risk of myopathy and cardiomyopathy increases, with MAO inhibitors, the risk of neurotoxicity increases, with ethanol - hepatotoxicity, with cardiac glycosides - glycoside intoxication increases.

TERMS OF RELEASE FROM PHARMACY

On prescription.

TERMS AND CONDITIONS OF STORAGE

List B. Inaccessible to children, at a temperature of no higher than 25 ° C.
Shelf life - 5 years. After expiration date the drug should not be used.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!